Neonatal phencyclidine treatment in mice induces behavioral, histological and neurochemical abnormalities in adulthood

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 9, 2009, Pages 1576-1583

  Nakatani Pawlak, Akiko ^a,b   Yamaguchi, Kazumasa ^b   Tatsumi, Yoshimi ^c   Mizoguchi, Hiroyuki ^d   Yoneda, Yukio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Nihon Bioresearch Inc   (Japan)

^c Narabyouri Research Co Ltd   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

Author keywords

Clozapine; Parvalbumin; Phencyclidine; Schizophrenia; Social interaction; Spine density

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR; CLOZAPINE; CYCLOSERINE; FLUMAZENIL; GLUTAMIC ACID; PARVALBUMIN; PHENCYCLIDINE; SHC 50911; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; HYPERACTIVITY; INTERNEURON; LOCOMOTION; MALE; MONOAMINE METABOLISM; MOUSE; NEUROCHEMISTRY; NEUROTRANSMISSION; NEWBORN; NONHUMAN; SOCIAL INTERACTION; WORKING MEMORY;

AGING; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN; BRAIN CHEMISTRY; INTERPERSONAL RELATIONS; MALE; MEMORY; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PHENCYCLIDINE; SCHIZOPHRENIA;

EID: 69949184393     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.1576     Document Type: Article

References (36)

1. Clancy B., Darlington R. B., Finlay B. L., Neuroscience, 105, 7-17 (2001).
2. Behar T. N., Scott C. A., Greene C. L., Wen X., Smith S. V., Maric D., Liu Q. Y., Colton C. A., Barker J. L., J. Neuroscience, 19, 4449-4461 (1999).
3. Reiprich P., Kilb W., Luhmann H. J., Cereb. Cortex, 15, 349-358 (2005).
4. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J. L., Johnson K. M., Neuroscience, 107, 535-550 (2001).
5. Wang C., McInnis J., West J. B., Bao J., Anastasio N., Guidry J. A., Ye Y., Salvemini D., Johnson K. M., J. Pharmacol. Exp. Ther., 304, 266-271 (2003).
6. Depoortère R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., Poncelet M., Heaulme M., Santucci V., Decobert M., Cudennec A., Voltz C., Boulay D., Terranova J. P., Stemmelin J., Roger P., Marabout B., Sevrin M., Vigé X., Biton B., Steinberg R., Françon D., Alonso R., Avenet P., Oury-Donat F., Perrault G., Griebel G., George P., Soubrié P., Scatton B., Neuropsychopharmacology, 30, 1963-1985 (2005).
7. Andersen J. D., Pouzet B., Neuropsychopharmacology, 29, 1080-1090 (2004).
8. du Bois T. M., Deng C., Han M., Newell K. A., Huang X. F., Eur. Neuropsychopharmacolology, 19, 256-265 (2009).
9. Noor J. I., Ikeda T., Mishima K., Aoo N., Ohta S., Egashira N., Iwasaki K., Fujiwara M., Ikenoue T., Stroke, 36, 2468-2474 (2005).
10. Yamada K., Tanaka T., Mamiya T., Shiotani T., Kameyama T., Nabeshima T., Br. J. Pharmacol., 126, 235-244 (1999).
11. Ballard T. M., Pauly-Evers M., Higgins G. A., Ouagazzal A. M., Mutel V., Borroni E., Kemp J. A., Bluethmann H., Kew J. N., J. Neurosci., 22, 6713-6723 (2002).
12. Qiao H., Noda Y., Kamei H., Nagai T., Furukawa H., Miura H., Kayukawa Y., Ohta T., Nabeshima T., Neuroreport, 12, 11-15 (2001).
13. Noda A., Noda Y., Kamei H., Ichihara K., Mamiya T., Nagai T., Sugiura S., Furukawa H., Nabeshima T., Neuropsychopharmacology, 24, 451-460 (2001).
14. Pitkänen M., Sirviö J., MacDonald E., Ekonsalo T., Riekkinen P. Sr., J. Neural Transm. Park. Dis. Dement. Sect., 9, 133-144 (1995).
15. Breese G. R., Knapp D. J., Overstreet D. H., Navarro M., Wills T. A., Angel R. A., Neuropsychopharmacology, 33, 867-876 (2008).
16. Frankowska M., Filip M., Przegalinski E., Pharmacol. Rep., 59, 645-655 (2007).
17. Selemon L. D., Begovic A., Goldman-Rakic P. S., Castner S. A., Neuropsychopharmacology, 32, 919-931 (2007).
18. Feldman M. L., Peters A., J. Comp. Neurol., 188, 527-542 (1979).
19. Condé F., Lund J. S., Jacobowitz D. M., Baimbridge K. G., Lewis D. A., J. Comp. Neurol., 341, 95-116 (1994).
20. DeFelipe J., J. Chem. Neuroanat., 14, 1-19 (1997).
21. Cull-Candy S., Brickley S., Farrant M., Curr. Opin. Neurobiol., 11, 327-335 (2001).
22. Luján R., Shigemoto R., López-Bendito G., Neuroscience, 130, 567-580 (2005).
23. Sin W. C., Haas K., Ruthazer E. S., Cline. H. T., Nature (London), 419, 475-480 (2002).
24. Komuro H., Rakic P., Science, 260, 95-97 (1993).
25. Lippman J., Dunaevsky A., J. Neurobiol., 64, 47-57 (2005).
26. Kitaichi K., Yamada K., Hasegawa T., Furukawa H., Nabeshima T., Jpn. J. Pharmacol., 66, 181-189 (1994).
27. Nagai T., Noda Y., Une T., Furukawa K., Furukawa H., Kan Q. M., Nabeshima T., Neuroreport, 14, 269-272 (2003).
28. Lewis S. W., Barnes T. R., Davies L., Murray R. M., Dunn G., Hayhurst K. P., Markwick A., Lloyd H., Jones P. B., Schizophr. Bull., 32, 715-723 (2006).
29. Volavka J., Czobor P., Sheitman B., Lindenmayer J. P., Citrome L., McEvoy J. P., Cooper T. B., Chakos M., Lieberman J. A., Am. J. Psychiatry, 159, 255-262 (2002).
30. Goff D. C., Cather C., Gottlieb J. D., Evins A. E., Walsh J., Raeke L., Otto M. W., Schizophr. Res., 106, 320-327 (2008).
31. Powell C. M., Miyakawa T., Biol. Psychiatry, 59, 1198-1207 (2006).
32. Endo K., Hori T., Abe S., Asada T., Synapse, 61, 357-366 (2007).
33. Flores G., Alquicer G., Silva-Gómez A. B., Zaldivar G., Stewart J., Quirion R., Srivastava L. K., Neuroscience, 133, 463-470 (2005).
34. Krystal J. H., D'Souza D. C., Mathalon D., Perry E., Belger A., Hoffman R., Psychopharmacology (Berlin), 169, 215-233 (2003).
35. Lewis D. A., Hashimoto T., Volk D. W., Nat. Rev. Neurosci., 6, 312-324 (2005).
36. Dong E., Agis-Balboa R. C., Simonini M. V., Grayson D. R., Costa E., Guidotti A., Proc. Natl. Acad. Sci. U.S.A., 102, 12578-12583 (2005).